First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal ...
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that affects the blood vessels. A person with HHT may have blood vessels that have not developed properly and may have no ...
Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.
WATERTOWN, Mass. , March 04, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with multispecific antibodies that address the ...
WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, today announced they will ...
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
New PRMRP designation creates dedicated pathway for HHT-focused research through the Department of Defense’s Congressionally Directed Medical Research Programs This is a defining moment…This federal ...
Hereditary Hemorrhagic Telangiectasia Disease (HHT) Market report will be very beneficial to both of the sides in the market that is an established firm and a relatively new entrant. It helps the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results